A Long-term Follow-up Study of Patients Who Received VOR33
NCT05309733 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 10
Last updated 2025-07-29
Summary
VOR33 long-term follow-up (LTFU) study
Conditions
- Leukemia, Myeloid, Acute
Interventions
- GENETIC
-
VOR33
VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell therapy product that lacks the CD33 myeloid protein.
Sponsors & Collaborators
-
Vor Biopharma
lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-04-15
- Primary Completion
- 2025-05-28
- Completion
- 2025-05-28
- FDA Drug
- Yes
Countries
- United States
- Canada
Study Locations
More Related Trials
-
Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans
NCT00541866 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Epigenetic Reprogramming in Relapse/Refractory AML
NCT03263936 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies
NCT05537766 ·Status: TERMINATED ·Phase: PHASE2
-
Lenalidomide in HTLV-1 Adult T-Cell Leukemia
NCT01274533 ·Status: COMPLETED ·Phase: PHASE2
-
Long Term Follow-up Study for Subjects Administered CLBR001
NCT06882317 ·Status: ENROLLING_BY_INVITATION
-
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
NCT03530683 ·Status: TERMINATED ·Phase: PHASE1
-
Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT04402541 ·Status: COMPLETED ·Phase: PHASE1
-
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
NCT00273936 ·Status: COMPLETED ·Phase: PHASE1
-
Genetic Test To Identify Previously Undetectable Minimal Residual Disease in Cell Samples From Younger Patients With Acute Lymphoblastic Leukemia
NCT01533168 ·Status: COMPLETED
-
Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia
NCT01003769 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias
NCT03761069 ·Status: TERMINATED ·Phase: PHASE1
-
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
NCT00536341 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
NCT03298516 ·Status: COMPLETED ·Phase: PHASE1
-
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
NCT05310591 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
NCT03922100 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
FT538 in Subjects With Advanced Hematologic Malignancies
NCT04614636 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
NCT00607997 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
NCT05326516 ·Status: COMPLETED ·Phase: PHASE1
-
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781 ·Status: RECRUITING ·Phase: PHASE4
-
Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients
NCT06180863 ·Status: WITHDRAWN ·Phase: PHASE2
-
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
NCT05317936 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Venetoclax to Augment Epigenetic Modification and Chemotherapy
NCT05317403 ·Status: RECRUITING ·Phase: PHASE1
-
A Long-term Follow-up Study of Patients Who Received MB-105
NCT07340814 ·Status: NOT_YET_RECRUITING
-
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
NCT04113616 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan
NCT06362044 ·Status: COMPLETED